Cibus

CBUS

Market cap $73.6M

Overview Fund Activity

1.40 USD

+0.03

2.19%

At close Updated Sep 16, 11:08 AM EDT

1 day

2.19%

5 days

-0.71%

1 month

0.72%

3 months

-11.39%

6 months

-41.18%

Year to date

-52.7%

1 year

-72.82%

5 years

-99.54%

10 years

-99.75%

About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Employees: 159

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

10% less funds holding

Funds holding: 67 [Q1] → 60 (-7) [Q2]

10.53% less ownership

Funds ownership: 36.74% [Q1] → 26.21% (-10.53%) [Q2]

22% less capital invested

Capital invested by funds: $22.6M [Q1] → $17.5M (-$5.07M) [Q2]

25% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 24

33% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 18

See Fund Rankings

Financial journalist opinion

Cibus Enters into Agreement with the Latin American Rice Hybrid Consortium to Provide Cibus' Herbicide Tolerance Trait

Cibus and Centro Internacional de Agricultura Tropical (CIAT) have entered into an agreement to introduce Cibus' proprietary herbicide tolerance trait into elite rice germplasm for Latin America Agreement represents another significant milestone as Cibus aims to bring Latin America rice growers new solutions for advanced weed management in Rice crops SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced a material transfer agreement with Centro Internacional de Agricultura Tropical (CIAT), an organization which, in collaboration with the Latin American Fund for Irrigated Rice (FLAR), participates in the Hybrid Rice Consortium for Latin America (HIAAL) and is dedicated to the advancement of rice hybrids in Latin America. Through this agreement Cibus will provide its HT3 clethodim herbicide tolerance trait to be introduced into HIAAL's elite rice germplasm.

Cibus Enters into Agreement with the Latin American Rice Hybrid Consortium to Provide Cibus' Herbicide Tolerance Trait

Cibus, Inc. (CBUS) Q2 2025 Earnings Call Transcript

Cibus, Inc. (NASDAQ:CBUS ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Cornelis Broos - Interim Chief Financial Officer Gregory F. Gocal - Co-Founder, Chief Scientific Officer & Executive VP Peter R.

Cibus, Inc. (CBUS) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Cibus (CBUS) Reports Q2 Loss, Lags Revenue Estimates

Cibus (CBUS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $1.14 per share a year ago.

Cibus (CBUS) Reports Q2 Loss, Lags Revenue Estimates

Cibus Reports Second Quarter Financial Results and Provides Year-to-Date Business Update for 2025

Streamlining operational focus on Rice herbicide tolerance traits and partner-funded and/or supported programs, expected to reduce annual cash usage to approximately $30 million by 2026

Cibus Reports Second Quarter Financial Results and Provides Year-to-Date Business Update for 2025

Cibus to Report Second Quarter 2025 Financial Results on August 14, 2025 After the Market Close and Host Conference Call

SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report second quarter 2025 financial results on Thursday, August 14, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m.

Cibus to Report Second Quarter 2025 Financial Results on August 14, 2025 After the Market Close and Host Conference Call

The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that it has completed the U.S. Food and Drug Administration's (FDA) Plant Biotechnology Consultation Program for its altered lignin alfalfa trait with the FDA notifying Cibus that it has no further questions concerning the use of altered lignin alfalfa in food or feed. To develop altered lignin alfalfa, Cibus (formerly Calyxt, Inc.) collaborated with S&W Seed Company to identify an alfalfa trait with an altered lignin profile providing potential increased nutrient availability for livestock.

The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed

Cibus and John Innes Centre Announce Ongoing Collaboration with Potential to Revolutionize Fertilizer Use in Farming

Researchers at the John Innes Centre (JIC) have discovered a genetic mutation with the potential to enhance nutrient uptake and reduce the need for artificial fertilizers Cibus and JIC have agreed on a collaboration with the potential to introduce the trait into several commercial crops Cibus previously announced the successful editing of Canola plants with this mutation and looks forward to further testing and trait validation SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. ("Cibus" or the "Company") (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today confirmed its continuing collaboration with the John Innes Centre (JIC). Cibus applauds the JIC breakthrough discovery, published earlier this year in the journal Nature, of a biological mechanism that makes plant roots more welcoming to beneficial soil microbes.

Cibus and John Innes Centre Announce Ongoing Collaboration with Potential to Revolutionize Fertilizer Use in Farming

Cibus, Inc. Announces Closing of $27.5 Million Public Offering

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the closing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus' board of directors (5,714,286 shares).

Cibus, Inc. Announces Closing of $27.5 Million Public Offering

USDA Designates Cibus' Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA's Biotechnology Regulations

This action follows the USDA's recent designation of Cibus' disease resistance traits in Canola as not regulated, continuing Cibus' product development momentum in the globally important Canola crop This action follows the USDA's recent designation of Cibus' disease resistance traits in Canola as not regulated, continuing Cibus' product development momentum in the globally important Canola crop

USDA Designates Cibus' Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA's Biotechnology Regulations

Cibus, Inc. Announces Pricing of $27.5 Million Public Offering

SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus' board of directors (5,714,286 shares).

Cibus, Inc. Announces Pricing of $27.5 Million Public Offering

See News Rankings

Charts implemented using Lightweight Charts™